Clinical Trials Logo

Hidradenitis Suppurativa clinical trials

View clinical trials related to Hidradenitis Suppurativa.

Filter by:

NCT ID: NCT03289585 Recruiting - Clinical trials for Hidradenitis Suppurativa

A National Registry For Patients With Hidradenitis Suppurativa

Start date: August 2015
Phase: N/A
Study type: Observational

The goal of this study is to get a better understanding of the skin condition, Hidradenitis Suppurativa, and to find out how the disease affects quality of life. We hope this information will help us improve our treatment for this skin condition

NCT ID: NCT03288337 Recruiting - Quality of Life Clinical Trials

Impact of Hidradenitis Suppurativa on Quality of Life Functions

Start date: April 2015
Phase: N/A
Study type: Observational [Patient Registry]

The goal of this study is to get a better understanding of the impact of the skin condition, Hidradenitis Suppurativa, on quality of life function of patients with this condition. Patients with HS will be asked questions about demographics including gender, age, and ethnicity. They will also be asked to complete questionnaires to determine how their skin condition affects their life. Study participation will last for 1 day, with potential for follow-up in the future.We hope this information will help us improve our treatment for this skin condition.

NCT ID: NCT03275870 Recruiting - Clinical trials for Hidradenitis Suppurativa

Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa

Start date: October 2017
Phase: Phase 1/Phase 2
Study type: Interventional

Hidradenitis suppurativa (HS) is an under-recognized and debilitating disease. Patients suffer from recurring painful abscesses and scarring in their armpits, under the breasts, groin and other areas of the body. The cause of the disease is still unknown and common treatments are only sometimes effective. Overactivity of the immune system has been associated with HS and molecules that cause inflammation have been found in the skin from people with HS. Current therapies have long-term risks including antibiotic resistance and the investigators aim to find new safe and effective therapies for HS. Hydroxychloroquine is a medication that has been used safely in other diseases for many years. The investigators believe that hydroxychloroquine has the potential to improve HS through multiple mechanisms. Patients enrolled in this study will be treated with hydroxychloroquine for 6 months. The investigators also aim to look at the blood of patients with HS to look for inflammatory molecules that we could possibly target for the treatment of HS. Blood samples will be taken at baseline and following 6 months of treatment.

NCT ID: NCT03248531 Not yet recruiting - Clinical trials for Hidradenitis Suppurativa

A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.

Start date: September 2017
Phase: Phase 2
Study type: Interventional

Hidradenitis suppurativa (HS) is a painful, long-term skin condition that causes abscesses and scarring on the skin.

NCT ID: NCT03238469 Recruiting - Clinical trials for Hidradenitis Suppurativa

Microwave Ablation in Mild Axillary Hidradenitis Suppurativa

WAVE
Start date: September 1, 2017
Phase: N/A
Study type: Interventional

With microwave ablation (MWA), using the heat generated from electromagnetic waves in the microwave energy spectrum, hair follicles and apocrine glands in the (hypo)dermis are ablated through thermolysis. MWA was recently approved for the treatment of axillary hyperhidrosis (miraDry) and removal of axillary hair (miraSmooth). By permanent removal of hairs and sweat glands, the investigators hypothesize a beneficial and long-term sustainable preventive effect of MWA in HS patients.

NCT ID: NCT03221621 Not yet recruiting - Clinical trials for Hidradenitis Suppurativa

Cost-effectiveness of Adalimumab and Surgery vs Adalimumab in HS

HS-COST
Start date: August 1, 2017
Phase: Phase 4
Study type: Interventional

The primary objective of this randomized controlled clinical trial in a real life setting is to evaluate the cost-utility of limumab monotherapy compared with the combination of adalimumab and a maximum of three surgeries after two years of treatment in adult patients with moderate to severe HS.

NCT ID: NCT03203122 Recruiting - Clinical trials for Hidradenitis Suppurativa

Intense Pulsed Light Therapy for Hidrosadenitis Suppurativa

Start date: August 7, 2017
Phase: N/A
Study type: Interventional

6 monthly treatments with IPL laser in patients with Hidradenitis Suppurativa. The effect in measured on several severity scores.

NCT ID: NCT03173144 Not yet recruiting - Psoriasis Clinical Trials

Chronic Inflammatory Disease, Lifestyle and Treatment Response

BELIEVE
Start date: June 1, 2017
Phase: N/A
Study type: Observational [Patient Registry]

Chronic inflammatory diseases (CID) - including inflammatory bowel diseases (Crohn's disease and ulcerative colitis), rheumatic conditions (rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis), inflammatory skin diseases (psoriasis, hidradenitis suppurativa) and non-infectious uveitis are treated with biologics targeting the pro-inflammatory molecule tumour necrosis factor-α (TNF), i.e. TNF inhibitors. Up to one third of the patients do, however, not respond to biologics and lifestyle is assumed to affect the treatment outcome. However, little is known on the effects of lifestyle as a prognostic factor (possibly enabling personalised medicine). The aims of this multidisciplinary collaboration are to identify lifestyle factors that support individualised forecasting of optimised treatment outcome on these costly drugs. This prospective cohort study will enrol CID patients assigned for TNF-α inhibitors. At baseline (Pre-treatment), patient characteristics are assessed using patient-reported outcome measures and clinical assessments on disease activity, quality of life, and lifestyle together with registry data on comorbidity and medication. Follow-up will be conducted at week 14-16 after treatment initiation (according to the current Danish standards). Evaluation of a successful treatment outcome response will - for each disease - be based on most frequently used primary endpoints; the major outcome of the analyses will be to detect differences in treatment outcome between patients with specific lifestyle characteristics. The overarching goal of this project is to improve the lives of patients suffering from CID, by providing evidence to support dietary recommendations likely to improve the clinical outcome. The study is approved by the local Ethics Committee (S-20160124) and the local Data Agency (2008-58-035). The study findings will be disseminated in peer-reviewed journals, via patient associations, and presented at national and international conferences.

NCT ID: NCT03146676 Recruiting - Clinical trials for Hidradenitis Suppurativa

The Ohio State University Dermatology Biorepository, Molecular Biology and Genetics of Hidradenitis Suppurativa

Start date: April 19, 2017
Phase: N/A
Study type: Observational

Analysis of Gene expression and microbiome profiling in hidradenitis suppurativa to identify immunological biomarkers of disease activity.

NCT ID: NCT03103074 Recruiting - Clinical trials for Hidradenitis Suppurativa

Pilot Study on Botulinum Toxin B as Treatment for Hidradenitis Suppurativa

Start date: May 24, 2017
Phase: N/A
Study type: Interventional

Randomized double blind placebo controlled pilot study/proof of concept-study to see if intradermal injection with Botulinum toxin B is an effective treatment of Hidradenitis suppurativa